Laquinimod
- The pivotal CONCERTO clinical study is continuing according to plan and results are expected in 2016
- Teva is holding a number of presentations of laquinimod at the AAN Annual Meeting on April 18-25
Tasquinimod
- Results from the Phase III study 10TASQ10 showed that treatment with tasquinimod reduced the risk of radiographic cancer progression or death compared to placebo (rPFS, HR=0.69, CI 95%: 0.60 - 0.80) in patients with metastatic castration resistant prostate cancer (mCRPC) who have not received chemotherapy, but did not extend overall survival (OS, HR=1.09, CI 95%: 0.94 - 1.28)
- Further development of tasquinimod for the treatment of prostate cancer has been discontinued. The collaboration agreement with Ipsen will accordingly cease.
ISI
- The project is currently focusing on building up a patent portfolio
Financial summary
MSEK | Jan. - Mar. | Jan. - Dec. | |||
2015 | 2014 | 2014 | |||
Net sales | 2.9 | 2.1 | 10.4 | ||
Operating loss | -57.4 | -59.2 | -228.5 | ||
Loss for the period | -58.0 | -60.2 | -231.5 | ||
Loss per share (SEK) | -0.64 | -0.80 | -3.02 | ||
Cash and cash equivalents | 270.5 | 298.5 | 328.5 |
For further information, please contact:
Tomas Leanderson, President and CEO Tel: +46 (0)46 19 20 95 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 The report is also available at www.activebiotech.com | Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 (0)46 19 20 00 Fax: +46 (0)46 19 11 00 |